Marinus Pharmaceuticals Inc (STU:61Y)
€ 0.292 0.076 (35.19%) Market Cap: 19.67 Mil Enterprise Value: 32.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Q4 2023 Marinus Pharmaceuticals Inc Earnings Call Transcript

Mar 05, 2024 / 09:30PM GMT
Release Date Price: €8.4 (-3.45%)
Operator

Ladies and gentlemen, greetings, and welcome to Marinus Pharmaceuticals Fourth Quarter and Full Year 2023 financial results and business update call. Today's call is being recorded (Operator Instructions) Thank you. And it is my pleasure to introduce your host, Sonya Weigle, Senior Vice President of Investor Relations. Human Resources and Corporate Affairs with Marinus, you may begin.

Sonya Weigle
Marinus Pharmaceuticals Inc - Senior Vice President of Investor Relations, Human Resource & Corporate Affairs

Thank you and good afternoon. With me from Marinus are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Joe Hulihan, head Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot